Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 141-153

  Darpo, Borje ^a,b   Zhou, Meijian ^b   Matthews, Jessica ^c   Zhi, Hui ^c   Young, Malcolm A ^c   Perry, Caroline ^c   Reinhardt, Rickey R ^c  

^a DANDERYD HOSPITAL   (Sweden)

^b ICardiac Technologies   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Albiglutide; GLP 1 receptor agonist; Healthy volunteers; QTc interval; Thorough QT study; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; PLACEBO;

ACUTE APPENDICITIS; ADULT; ARTICLE; ASTHMA; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTACT DERMATITIS; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEADACHE; HEART REPOLARIZATION; HUMAN; IMMUNOASSAY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QT PROLONGATION; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VOMITING;

EID: 84901769522     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0055-1     Document Type: Article

References (23)

1. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:4810–7.
2. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32:1880–6.
3. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53:2492–500.
4. Darpo B. Spectrum of drugs prolonging the QT interval and the incidence of torsades de pointes. Eur Heart J. 2001;3(Suppl K):70–80.
5. International Conference on Harmonisation. ICH E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions & answers. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Q_As_R1_step4.pdf. Accessed October 22, 2013.
6. International Conference on Harmonisation. ICH harmonised tripartite guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf. Accessed October 22, 2013.
7. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008;84:475–80.
8. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol. 2006;46:498–507.
9. Florian JA, Tornoe CW, Brundage R, Parekh A, Garnett CE. Population pharmacokinetic and concentration—QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol. 2011;51:1152–62.
10. Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol. 2010;159:49–57.
11. Graham RA, Chang I, Jin JY, et al. Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers. J Cardiovasc Pharmacol. 2013;61:83–9.
12. Hofmann C, Banken L, Hahn M, Swearingen D, Nagel S, Martin-Facklam M. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. Clin Ther. 2012;34:2061–71.
13. Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92:696–706.
14. Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012;73:203–9.
15. Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol. 2009;49:1353–62.
16. Linnebjerg H, Seger M, Kothare PA, Hunt T, Wolka AM, Mitchell MI. A thorough QT study to evaluate the effects of single dose exenatide 10 mg on cardiac repolarization in healthy subjects. Int J Clin Pharmacol Ther. 2011;49:594–604.
17. Tornoe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV. Creation of a knowledge management system for QT analyses. J Clin Pharmacol. 2011;51:1035–42.
18. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990;9:811–8.
19. Darpo B, Karnad DR, Badilini F, et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modeling in a Phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2013 Jul 2 [Epub ahead of print]
20. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm. 2006;3:1003–7.
21. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9:209–22.
22. Deacon CF, Marx N. Potential cardiovascular effects of incretin-based therapies. Expert Rev Cardiovasc Ther. 2012;10:337–51.
23. Darpo B, Sager P, Macconell L, et al. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol. 2012;74:979–89.